IP Library › Granted Patent US 12,706,227
Granted Patent B2
US 12,706,227 · App. 18/164,164 · Granted Aug 11, 2026

Methods and compositions for treating cancer with von Willebrand factor peptide linked to immunotherapeutic antibodies

Inventors: Jeffrey A. Hubbell (Chicago, IL); Jun Ishihara (Chicago, IL); Ako Ishihara (Chicago, IL); Kazuto Fukunaga (Chicago, IL); Melody Swartz (Chicago, IL)
Assignee: The University of Chicago
G21F5/12A61K9/0019A61K38/18A61K38/195A61K38/36A61K39/3955A61K45/06A61P35/00C07K14/475C07K14/522C07K14/755C07K16/2818C07K16/2827C07K16/2878G21F7/005A61K2039/507A61K2039/545C07K2317/24C07K2317/75C07K2317/92C07K2319/30C07K2319/70G21F5/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,706,227
App. No.
18/164,164
Filed
Feb 3, 2023
Granted
Aug 11, 2026
Kind
B2
Art Unit
1647
USPC
424/134.1
Abstract

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Claims (22)

1 . A composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide, wherein the ECM-affinity peptide comprises a von Willebrand factor (VWF) peptide.

2 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 85% identical to SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO: 14, or fragments thereof.

3 . The composition of claim 1 , wherein the immunotherapeutic antibody comprises a CTLA4, PD-L1, or PD-1 antibody.

4 . The composition of claim 1 , wherein the immunotherapeutic antibody comprises a CD40 agonistic antibody.

5 . The composition of claim 1 , wherein the composition further comprises a second immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide.

6 . The composition of claim 5 , wherein the composition comprises:

a CTLA4 antibody operatively linked to an ECM-affinity peptide; and

(a) a PD-L1 antibody operatively linked to an ECM-affinity peptide or (b) a PD-1 antibody operatively linked to an ECM-affinity peptide.

7 . A method for treating cancer in a subject comprising administering the composition of claim 1 to a subject.

8 . The composition of claim 1 , wherein the immunotherapeutic antibody comprises an αGITR, αCD134, or αCD137 antibody.

9 . The composition of claim 2 , wherein the VWF peptide comprises a peptide that that has the amino acid sequence of SEQ ID NO:3, SEQ ID NO:11, or SEQ ID NO: 14.

10 . The composition of claim 1 , wherein the peptide is covalently linked to the antibody.

11 . The composition of claim 1 , wherein the peptide is crosslinked to the antibody through a bifunctional linker.

12 . The composition of claim 3 , wherein the immune checkpoint inhibitory antibody comprises pembrolizumab, nivolumab, atezolizumab, ipilimumab, tremelimumab, avelumab, or durvalumab.

13 . The composition of claim 1 , wherein the antibody is a humanized antibody.

14 . The composition of claim 1 , wherein the ratio of peptide to antibody is about 1:1 to 10:1.

15 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 95% identical to SEQ ID NO:14.

16 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 98% identical to SEQ ID NO:14.

17 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 95% identical to SEQ ID NO:14, and the immunotherapeutic antibody comprises a CTLA4 antibody.

18 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 95% identical to SEQ ID NO:14, and the immunotherapeutic antibody comprises a PD-L1 antibody.

19 . The composition of claim 1 , wherein the VWF peptide comprises a peptide that is at least 95% identical to SEQ ID NO:14, and the immunotherapeutic antibody comprises a PD-1 antibody.

20 . A composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide, wherein the ECM-affinity peptide comprises a von Willebrand factor (VWF) peptide, and wherein the VWF peptide comprises a peptide that is at least 85% identical to SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO: 14, or fragments thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2023
From: HUBBELL, JEFFREY A.; ISHIHARA, JUN; ISHIHARA, AKO; FUKUNAGA, KAZUTO; SWARTZ, MELODY
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 063594/0672 →
Continuity (3)
Division 16606539 · Apr 20, 2018
Provisional Application 62487823 · Apr 20, 2017
Related Publication 20230377764A1 · Nov 23, 2023
References Cited (55)
US 5086620A · Spears · 1992 [cited by applicant]
US 5716855A · Lerner et al. · 1998 [cited by applicant]
US 6033645A · Unger et al. · 2000 [cited by applicant]
US 6106474A · Koger et al. · 2000 [cited by applicant]
US 6123923A · Unger et al. · 2000 [cited by applicant]
US 10980877B2 · Swartz et al. · 2021 [cited by applicant]
US 11484599B2 · Swartz et al. · 2022 [cited by applicant]
US 11574747B2 · Hubbell et al. · 2023 [cited by applicant]
US 11732029B2 · Hubbell et al. · 2023 [cited by applicant]
US 20010053535A1 · Bashier et al. · 2001 [cited by applicant]
US 20020076830A1 · Mauze et al. · 2002 [cited by applicant]
US 20020076930A1 · Jo et al. · 2002 [cited by applicant]
US 20030104512A1 · Freeman et al. · 2003 [cited by applicant]
US 20030108911A1 · Ingo et al. · 2003 [cited by applicant]
US 20040030268A1 · Weng et al. · 2004 [cited by applicant]
US 20040051154A1 · Yamakawa et al. · 2004 [cited by applicant]
US 20040115094A1 · Gumbrecht et al. · 2004 [cited by applicant]
US 20050107694A1 · Jansen et al. · 2005 [cited by applicant]
CN 104603148A · 2015 [cited by applicant]
JP 2003532681 · 2003 [cited by applicant]
WO WO1996026179 · 1996 [cited by applicant]
WO WO1998057666 · 1998 [cited by applicant]
WO WO1999030620 · 1999 [cited by applicant]
WO WO2001058458 · 2001 [cited by applicant]
WO WO2001085192 · 2001 [cited by applicant]
WO WO2002056670 · 2002 [cited by applicant]
WO WO2002073153 · 2002 [cited by applicant]
WO WO2014006082 · 2014 [cited by applicant]
WO WO2016054107 · 2016 [cited by applicant]
WO WO2016054555 · 2016 [cited by applicant]
WO WO2017009842 · 2017 [cited by applicant]
Luheshi et al., “Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse or orthotopic pancreatic tumour model,” Oncotarget, 7(14):18508-1… [cited by applicant]
Briquez et al., “Extracellular Matrix-Inspired Growth Factor Delivery Systems for Skin Wound Healing,” Advances in Wound Care, Aug. 2015, 4(8):479-489. [cited by applicant]
Martino et al., “Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing,” Science, Feb. 2014, 343: 885-888. [cited by applicant]
Office Communication issued in European Patent Application No. 18787963.0, dated Aug. 23, 2024. [cited by applicant]
Arridge et al. Optical imaging in medicine: II Modelling and reconstruction:, Phys. Med. Biol. vol. 42, 1997, 99. 841-853. [cited by applicant]
Arridge, “Optical tomography in medical imaging,” Inverse problems, vol. 15, 1999, R41-R93. [cited by applicant]
Calliada et al. “Ultrasound contrast agents basic principles”, European Journal of Radiology, vol. 27, pp. S157-S160. [cited by applicant]
Clegg; “Fluorescence resonance energy transfer and nucleic acids”, Methods in Enzymology, vol. 211. [cited by applicant]
Cruz et al., “Interaction of the von Willebrand Factor (vWF) with Collagen” [cited by applicant]
Demos et al.; “In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement”, Journal of the American College of Cardiology, vol. 33, No. 3, 1999. [cited by applicant]
European Search Report issued in Corresponding European Application No. 18787963.0, dated Nov. 20, 2020. [cited by applicant]
Harvey et al; “Advances in ultrasound”, Dept. Of Imaging, London, UK, Sept. 9, 2001, Clinical Radiology, 2002, 57, pp. 157-177. [cited by applicant]
Hebden et al. “Optical imaging in medicines: I. Experimental techniques”, Phys. Med. Biol. 42, 1997, pp. 825-840. [cited by applicant]
John et al. “Rapid transbilayer movement of the fluorescent sterol dehydroergosterol in lipid membranes,” Biophysical Journal, vol. 83, Sep. 2022, pp. 1525-1534. [cited by applicant]
Jong et al; “New ultrasound contrast agents and technological innovations”, Dept of Cardiology and Experimental Echocardiography, Utrecht, NL, Ultrasonics 34, 1996, pp. 587-590. [cited by applicant]
Liang et al. “A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix”, Scientific Reports, vol. 6, No. 1, Feb. 17, 2016. [cited by applicant]
Lu et al., “The extracellular matrix: A dynamic niche in cancer progression”, [cited by applicant]
Machha et al., “The Von Willebrand Factor A 1-Collegen Ill Interaction is Independent of conformation and Type 2 Von Willebrand Disease Phenotype” [cited by applicant]
Moran et al; “In vitro acoustic characterization of four intravenous ultrasonic contrast agents at 30 mhz”, Ultrasound In Med. & Biol., vol. 28, No. 6, pp. 785-791, Apr. 3, 2002. [cited by applicant]
Office Action issued in corresponding Chinese Application No. 2018800809597, dated Apr. 14, 2022. [cited by applicant]
Office Action issued in Corresponding Japanese Application No. 2019-557434, dated May 39, 2022 (English Translation Provided). [cited by applicant]
Wong et al; “Molecular topography imaging by intermembrane fluorescence resonance energy transfer”, Dept. of Chemistry, Univ. of California, Berkeley, CA, PNAS, Oct. 29, 2002, vol. 99, No. 22, pp. 14147-14152. [cited by applicant]
Xiong et al. “Function of cancer cell-derived extracellular matrix in tumor progression” [cited by applicant]
Yonezawa et al., “Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy” [cited by applicant]